Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Divigel · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Divigel | DRUG | - |
Inclusion Criteria: * Postmenopausal women * Have moderate to severe hot flashes * Normal Pap Smear Exclusion Criteria: * Abnormal mammogram * Abnormal clinical breast exam * BMI \>35
Divigel is used for the treatment of postmenopausal symptoms. It is an investigational small molecule being developed by Smith & Nephew SNATS, Inc. The drug is currently in Phase 3 clinical development, and it has been studied in a completed Phase 3 trial.
Divigel is being developed by Smith & Nephew SNATS, Inc., a company listed on the stock exchange under the ticker SNN. The drug is currently in Phase 3 clinical development for the treatment of postmenopausal symptoms.
Divigel is in Phase 3 clinical development. It has completed one Phase 3 trial, and the drug is not yet approved. It remains investigational and is being studied for the treatment of postmenopausal symptoms.
Divigel has been studied in a completed Phase 3 clinical trial with the identifier NCT00727129. This trial evaluated the drug for the treatment of postmenopausal symptoms and enrolled 495 female participants aged 18 years and older.
Divigel is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The drug has completed a Phase 3 trial for postmenopausal symptoms, but approval status has not been established.